Systematic perturbation screens provided comprehensive resources for the elucidation of cancer driver genes. However, few algorithms have been developed to robustly interrogate such datasets, particularly with limited number of samples. Here we developed a computational tool called APSiC (Analysis of Perturbation Screens for identifying novel Cancer genes) and applied it to the large-scale deep shRNA screen DRIVE 1 to unveil novel genetic and non-genetic driver genes. APSiC identified both well-known and novel drivers across all cancer types and within individual cancer types. The analysis of individual cancer types revealed that cancer drivers segregate by cell of origin and that genes involved in mRNA splicing may be oncogenic or tumor suppressive depending on the cancer type. We discovered and functionally demonstrated that LRRC4B is a novel putative tumor suppressor gene in breast cancer. The analysis of DRIVE using APSiC is provided as a web portal and represents a valuable resource for the discovery of novel cancer genes. 3 Advances in large-scale functional screening technologies have enabled the discovery of gene requirements across diverse cancer entities 2,3 . Systematic perturbation screens assess how genetic alterations or expression modulation of individual genes lead to phenotypic changes, revealing novel factors in carcinogenesis. McDonald et al. carried out the project DRIVE (deep RNAi interrogation of viability effects in cancer), a large perturbation screen targeting 7,837
copy number amplifications, respectively, while mutation tumor suppressor genes are those for which increased viabilities are preferentially observed in samples with deleterious mutations. To identify such genetic drivers, we test, for a given gene, whether ranks of the samples with and without the specific class of genetic alteration are significantly different using a one-sided Bates test (Fig. 1b) . For mutation and amplification oncogenes, we compute the lower-tailed P values (i.e. the ranks preferentially suggest reduced viability upon gene knockdown), while for mutation tumor suppressor genes, we compute the upper-tailed P values (i.e. the ranks preferentially suggest increased cell viability upon knockdown). For the non-genetic drivers, we test whether gene knockdown in samples without genetic alteration in the gene has any impact on cell viability by computing lower and upper-tailed Irwin-Hall test P values for oncogenes and tumor suppressor genes, respectively ( Fig. 1c) . Optionally, we further test whether the expression of candidate non-genetic oncogenes or tumor suppressor genes is respectively enhanced or repressed in human tumors compared to the corresponding normal tissue type.
We applied APSiC to the DRIVE perturbation screens and the genetic data from the Cancer Cell Line Encyclopedia 4 to identify genetic driver genes. The dataset consists of 383 cell lines across 26 cancer types ( Fig. 2a) . In a pan-cancer analysis, APSiC reassuringly identified the well-known mutation oncogenes BRAF, CTNNB1, KRAS, NRAS, PIK3CA and TP53 as the top candidates (Figs. 2b-c, Supplementary Table S1 ). Additionally, DDX27, DCAF8L2 and RBM39 were detected as mutation oncogenes ( Supplementary Fig. S1 and Supplementary   Table S1 ). The top amplification oncogene were KRAS, BRAF, CDK4, YAP1, IL6 and HAS2 (Figs. 2b, d and Supplementary Table S1 ), while the only mutation tumor suppressor was ARID1A (Figs. 2b, e and Supplementary Table S1 ). However, the identification of mutation tumor suppressor genes in a knockdown screen is likely to have limited utility given that mutation tumor suppressor genes are frequently associated with loss of the wild-type allele. 5 One of the main strengths of APSiC is the identification of dependencies in small sample sets.
We therefore applied APSiC to the DRIVE data to identify genetic driver genes for individual cancer types. Across the 26 cancer types, we found at least one mutation oncogene, mutation tumor suppressor gene and amplification oncogene in 15, 14 and 11 cancer types, respectively ( Fig. 2f) . KRAS, BRAF and TP53 were identified as a mutation oncogene in 4, 2 and 2 cancer types, respectively. We identified MCL1 as the top amplification oncogene in the squamous subtype of non-small cell lung cancer and BRCA1 as the top mutation tumor suppressor in breast cancer, but no amplification oncogene or mutation tumor suppressor was identified in more than one cancer type.
While whole-exome sequencing of 10,000+ cancers has revealed the global landscape of genetic driver genes 5 , a systematic analysis of non-genetic driver genes (i.e. driver genes for which the basis for oncogenicity is non-genetic) is lacking. By assessing the rank profiles of cell lines wild-type for a given gene using APSiC, we evaluated the non-genetic dependencies across cancer types in the DRIVE data. Consensus clustering of the most variable genes in terms of APSiC P values revealed that such non-genetic dependencies segregate by organ systems or cell-of-origin into four clusters (Fig. 3a) . In particular, non-epithelial cancers including leukemias/lymphomas, sarcomas, gliomas and neuroblastomas form a cluster distinct from epithelial cancers including those of the lungs, the breasts and gastrointestinal tract. This is consistent with the observation that multi-omics cancer classification is primarily driven by cell-of-origin and anatomic regions 6 . Furthermore, the top-level segregation of the cancer types was largely driven by the context-dependency of mRNA-splicing genes. We observed that mRNA-splicing genes such as PRPF6 (Pre-MRNA Processing Factor 6) and SART3 (Spliceosome Associated Factor 3, U4/U6 Recycling Protein) were tumor suppressive in the cluster enriched for non-epithelial cancers while they were oncogenic in the epithelial cancer cluster (Fig. 3b) . The context-dependency highlights the divergent role of mRNAsplicing in carcinogenesis between cancer types. Our results also underscore the necessity 6 for an algorithm powerful enough to analyze perturbation screens for small numbers of samples in a cancer type-specific manner.
Based on the DRIVE screen alone, we identified a median of 28 non-genetic oncogenes (range 6-557) and 35 non-genetic tumor suppressor genes (range 1-471) per cancer type.
However, we reasoned that the many non-genetic onco-and tumor suppressor genes would also be over-and under-expressed, respectively, in the corresponding cancer types. For the 12 cancer types for which gene expression data for the cancer and corresponding non-cancer counterparts were available from the TCGA (Supplementary Fig. S2 ), we further restricted the putative non-genetic onco-and tumor suppressor genes to those that were over-and under-expressed, respectively, relative to their non-cancer counterparts. After this filtering step, there were a median of 13 non-genetic oncogenes (range 2-117) and 3 non-genetic tumor suppressor genes (range 0-42, Fig. 4 ) per cancer type. We identified several wellknown oncogenes, including CDK1 (a master regulator of cell cycle) and SMC1A (a component of the cohesin complex involved in cell cycle checkpoint and genome stability) 7 , and some that have been shown to have oncogenic properties in some cancer types, such as MKI67IP (or NFIK) 8 . We also identified TEAD3, a lesser described member of the TEAD family involved in hippo signalling, as oncogenic in liver cancer 9 . Among the top candidate tumor suppressors were FOXP2 in endometrial cancer and XRCC5 in kidney carcinoma. FOXP2 knockdown has been shown to promote tumor initiation and metastasis in breast cancer 10 while XRCC5, encoding the protein Ku80, is a key DNA damage repair protein. However, we also identified many genes that have not been associated with carcinogenesis.
As a proof-of-concept to validate APSiC, we selected LRRC4B, one of the top putative nongenetic tumor suppressor genes in breast cancer that has not been associated with carcinogenesis. Nearly all breast cancer cell lines displayed significantly increased cell viability upon LRRC4B knockdown and breast cancers in TCGA showed lower expression compared to normal breast tissue ( Supplementary Fig. S3a ). We selected the breast cancer cell lines 7 MDA-MB231, BT-549 and MCF-7 with high, moderate and low endogenous LRRC4B expression to investigate its role in breast carcinogenesis ( Supplementary Fig. S3b ). We silenced LRRC4B in MDA-MB231 and BT-549 using siRNA, reducing LRRC4B protein expression by 40% and 60%, respectively, 72 hours post-transfection ( Figs. 5a, e ). In both models, LRRC4B downregulation significantly increased the proliferation and migration rates LRRC4, an important paralog of LRRC4B, has been shown to have an oncosuppressor role in glioma 11, 12, 13, 14 , suppressing cell proliferation by delaying cell cycle in late G1 phase 11, 15 . To test whether LRRC4B may play the same role in breast, we analyzed cells with LRRC4B overexpression or downregulation stained with DAPI by flow cytometry (FACS). LRRC4B knockdown in MDA-MB231 and BT-549 promoted cell transition into S phase (Figs. 5d, h) , while LRRC4B overexpression in MCF-7 significantly retained cells in G1 phase ( Fig. 5l ), suggesting a similar mechanism.
A common mechanism of oncogenicity is resistance to apoptosis 16 . To test whether modulation of apoptosis is a mechanism of action of LRRC4B as an oncosuppressor, we induced apoptosis with doxorubicin and measured it using Annexin V and propidium iodide co-staining followed by FACS analysis (Fig. 6a) . Forty eight hours after treatment, LRRC4Boverexpressing MCF-7 cells showed 10% more apoptotic and 10% fewer live cells, suggesting that LRRC4B overexpression could sensitize cells to doxorubicin-induced apoptosis (Fig. 6b) .
By contrast, LRRC4B-downregulating MDA-MB231 and BT-549 cells showed increased resistance to doxorubicin and had 25% and 10% fewer apoptotic and 25% and 10% more live cells, respectively ( Fig. 6b) . Our results provide compelling evidence that APSiC identified LRRC4B as a novel oncosuppressor gene in breast cancer.
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Here we provide a powerful statistical analysis for the scientific community to explore and functionally characterize genes that may be involved in carcinogenic processes and may pave the way for the discovery of novel cancer-related biomarkers and drug targets.
Methods

The APSiC algorithm
We introduce a novel computational tool called APSiC for Analysis of Perturbation Screens for identifying novel Cancer genes. To begin, we briefly describe some necessary definitions and background material from ordered statistics.
We consider the knockdown experiments of p genes across N cell lines. Let "# be viability of cell line i∈{1,…,N} upon knocking down gene j∈{1,…, p} and "# be a binary variable indicating whether a specific genetic alteration (i.e. mutation or copy number alteration) is present in gene j of cell line i. In this study, we only consider deleterious (e.g. nonsense, frameshift, splice site and mutations affecting start or stop codons) and missense mutations. Waterfall plots are often used to show viabilities of knockdown experiments for a single gene across different cell lines and are aimed to illustrate different gene dependencies. As an example, waterfall plot for gene TP53 is shown in Fig. 1a (left). Each vertical bar corresponds to a cell line and is colored by the pre-existing mutation types present in TP53. Fig. 1a indicates cell lines with the presence of deleterious or missense mutations in TP53 tend to have lower viabilities upon knockdown of this gene. While waterfall plot is a useful visualization tool for demonstrating gene dependencies, it lacks sufficient interpretability in certain cases, particularly when the number of cell lines is limited. In this paper, we introduce a new waterfall plot, named rank viability profile or simply rank profile, to address this issue.
To make viability scores comparable across cell lines, we compute normalized rank values per cell lines denoted as "# , representing the rank of viability for gene j among all knockdown experiments in cell line i. For mathematical convenience and without loss of generality, we normalized ranks to the range of [0, 1]. When the number of knockdown genes is high, normalized ranks have many distinct levels in the interval [0, 1] and we assume normalized ranks are continuous. Let (,* , +,* , . . . , -,* denote random variables associated to ranks of a gene A in N cell lines. We drop subscript A and denote ranks as ( , + , . . . , -for the simplicity of notation. By placing ranks, " , in ascending orders and renaming them, we obtain ( < + < . . . < -where " is called ith ordered statistic. It is easy to see that ( = ( ( , . . . , -) and -= ( ( , . . . , -). The probability density function of ordered statistic " in general is given as where f(r) and F(r) denote probability density and cumulative distribution functions, respectively. If there is no dependency between knocking down of a gene and the viability of the cell, we can assume " ∼ (0, 1) for = 1, . . . , , hence we have " ∼ ( , − + 1) .
Using this result, we can construct a no-change viability band at statistical significance α using the quantiles of " at the /2 and 1 − /2 for = 1, . . . , . Now we define a new waterfall plot, called rank viability profile or simply rank profile, as a waterfall plot using normalized ranks, realizations of " for a gene, overlaid with no-change viability band (Fig. 1a) .
The APSiC algorithm identifies potential cancer genes by assessing deviation of respective rank profiles from what is expected by chance. The algorithm can identify both genetic and non-genetic drivers ( Fig. 1b-c) . We consider three categories for genetic drivers.
• Mutation oncogene: defined as genes for which reduced viabilities are observed preferentially in samples with missense mutation.
• Amplification oncogene: defined as genes for which reduced viabilities are observed preferentially in samples with copy number amplification.
• Mutation tumor suppressor: defined as genes for which increased viabilities are observed preferentially in samples with deleterious mutation.
We consider two categories for non-genetic drivers, namely
• Non-genetic oncogene: defined as genes for which reduced viabilities are observed in samples without a genetic alteration in the respective gene.
• Non-genetic tumor suppressor: defined as genes for which increased viabilities are observed preferentially in samples without a genetic alteration in the respective gene.
For genetic drivers, the APSiC algorithm considers rank profiles of mutated and wild-type samples with respect to an input gene (Fig. 1b) To identify non-genetic drivers, we only consider the wild-type (i.e. without non-synonymous mutations and without copy number amplification (GISTIC copy number state 2) or deep deletions (GISTIC copy number state -2)) samples with respect to an input gene (Fig. 1c) .
The null hypothesis is that the knockdown of a gene g does not have any impact on the viability of the samples. We define the test statistic as = ( + + +. . . + H and MNO as the observed test statistic. Under the null hypothesis, T follows an Irwin-Hall distribution ∼ ( ), which represents the summation of independent uniform random variables on the unit interval.
For large values of m, S is approximately distributed as ( /2, /12). To identify non-genetic oncogenes, we require significant lower-tailed P values, ( ≤ MNO ) for wild-type cell lines with respect to the input gene. Additionally, for the respective tissue type, the overall expression at the RNA level of a putative oncogene in tumor samples is required to be significantly higher than the one in normal tissue samples using the t test. On the contrary, for identifying non-genetic tumor suppressors, we require significant upper-tailed P values, ( ≥ MNO ), for wild-type cell lines with respect to the input gene as well as lower RNA expression of tumor samples in comparison to normal tissue samples using the t test.
Downloading and preprocessing of DRIVE and TCGA data
We considered the viability profiles of 383 cell lines in the project DRIVE 1 for which their genetic profiles were available at the Cancer Cell Line Encyclopedia (Fig. 2a) 4 . We computed aggregated gene-level viability scores for each experiment by the RSA and ATARiS algorithms 18, 19 . The RSA and ATARiS scores are available for 7726 and 6557 genes, 13 respectively. We used the same method as defined in the project DRIVE to remove essential genes, defined as genes with an RSA value of ≤ 3 in more than half of cell lines. Fig. S2) . The data were downloaded using the TCGAbiolinks package in R 20 . The normalized expression level of genes in CPM (counts per million) were used for the identification of non-genetic drivers.
Multiple testing
To address the multiple comparisons problem, we chose a significance level such that the expected number of false positives due to multiple testing for each cancer and feature is equal to one. To this end, we chose a significance level of 1/ , or 0.05 if 1/ >0.05, where is the number of genes tested for identification of drivers. Using this approach, we were able to keep many interesting hits while keeping the number of false positive cases low.
Clustering and pathway analysis
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Clustering was performed using ConsensusClusterPlus 21 using 1-Spearman correlation as the distance metric and the Ward hierarchical clustering algorithm. The number of clusters was determined based on the relative change in area under the consensus cumulative distribution function over the number of evaluated clusters. Pathway analysis was performed using g:Profiler 22 . 
Software and data availability
Cell lines
Breast cancer derived cell lines (MCF-7, BT-549 and MDA-MB231) were maintained in a 5% CO2-humidified atmosphere at 37°C and cultured in DMEM supplemented with 10% FBS, 1%
Pen/Strep (Bio-Concept) and 1% MEM-NEAA (MEM non-essential amino acids, ThermoFisher Scientific). All cell lines were confirmed negative for mycoplasma infection using the PCR-based Universal Mycoplasma Detection kit (American Type Culture Collection, Manassas, VA) as previously described 23 . hours for protein analysis. To avoid cytotoxicity, transfection medium was replaced with complete medium after 8 hours.
Transient gene knockdown by siRNAs
Protein extraction and western blot
Proteins were extracted using Co-IP buffer (100 mmol/L NaCl, 50 mmol/L Tris pH 7. 
Proliferation assay
Cell proliferation was assayed using the xCELLigence system (RTCA, ACEA Biosciences, San Diego, CA, USA) as previously described. 24 Cells were first seeded and transfected in 6 well plates and 24 h after transfection 5x10 3 
Cell cycle analysis
Seventy-two hour after transfection, cells were collected, stained with DAPI and analyzed by flow cytometry using the BD FACS Canto II cytometer (BD Biosciences, USA). Briefly cells were harvested and washed 2X in PBS to get rid of serum proteins at 1200 rpm for 5 minutes.
Pellets (up to 3x10 6 cells) were resuspended in 1. 
